Clinical curative effect of HAT therapy on septic shock

doi:10.11958/20240083

Abstract

Abstract:

Objective To explore the curative effect of hydrocortisone ascorbic acid, vitamin C and vitamin B1 (HAT) therapy on septic shock and its influence on the time of vasoactive drug application, hemodynamic parameters and short-term prognosis. Methods According to different treatment plans, 92 patients with septic shock were divided into the HAT group and the routine treatment group, 46 cases in each group. The routine treatment group was given routine treatments [anti-infection, fluid replacement, stabling blood pressure and continuous renal replacement therapy (CRRT)], while the HAT group was additionally given HAT therapy. All patients were treated continuously for 3 d. The indexes related the curative effect, scores of acute physiology and chronic health evaluation Ⅱ(APACHE Ⅱ) and sequential organ failure assessment (SOFA), levels of mean arterial pressure (MAP), heart rate (HR), central arterial pressure (CAP), D-lactic acid (D-Lac), creatinine (Cr), hypersensitive C-reactive protein (hs-CRP) and procalcitonin (PCT) before and after treatment, incidence of adverse reactions and 28 d survival rate by follow-up were compared between the two groups. Results The circulation stabilization time, use time of vasoactive drugs and hormones, mechanical ventilation time, CRRT time, treatment time in ICU and total hospitalization time were shorter in the HAT group than those in the routine treatment group (P<0.05). After 7 d of treatment, scores of APACHE Ⅱand SOFA, levels of HR, D-Lac, Cr, hs-CRP and PCT were lower in the HAT group than those in the routine treatment group, while MAP and CAP were higher than those in the routine treatment group (P<0.05). The 28-day survival rate was 65.22% in the HAT group, which was higher than that in the routine treatment group (45.65%, P<0.05). Conclusion HAT therapy can improve clinical curative effect in patients with septic shock, shorten use time of vasoactive drugs, improve hemodynamic parameters and short-term prognosis.

Key words: shock, septic, hydrocortisone, vitamin C, vitamin B1, hemodynamics, short-term prognosis

CLC Number:

R453

Figures/Tables 6

References 25

[1]	CHIU C, LEGRAND M. Epidemiology of sepsis and septic shock[J]. Curr Opin Anaesthesiol, 2021, 34(2):71-76. doi:10.1097/ACO.0000000000000958.
[2]	宋凯, 湛立娜, 章静, 等. 脓毒症肺损伤相关信号转导通路研究进展[J]. 中国中西医结合外科杂志, 2023, 29(6):854-858.
	SONG K, ZHAN L N, ZHANG J, et al. Research progress on signal transduction pathways related to sepsis induced lung injury[J]. Chinese Journal of Integrated Traditional Chinese and Western Medicine Surgery, 2023, 29(6):854-858. doi:10.3969/j.issn.1007-6948.2023.06.026.
[3]	THOMPSON K, VENKATESH B, FINFER S. Sepsis and septic shock:current approaches to management[J]. Intern Med J, 2019, 49(2):160-170. doi:10.1111/imj.14199.
[4]	王静, 辛绍斌, 孙强, 等. 以多黏菌素B为基础联合治疗耐碳青霉烯革兰阴性菌脓毒症的临床疗效分析[J]. 天津医药, 2022, 50(1):88-93.
	WANG J, XIN S B, SUN Q, et al. Clinical efficacy of polymyxin B combination therapy in the treatment of carbapenem-resistant gram-negative bacteria sepsis[J]. Tianjin Med J, 2022, 50(1):88-93. doi:10.11958/20211589.
[5]	JOFFRE J, HELLMAN J, INCE C, et al. Endothelial responses in sepsis[J]. Am J Respir Crit Care Med, 2020, 202(3):361-370. doi:10.1164/rccm.201910-1911TR.
[6]	OCZKOWSKI S, ALSHAMSI F, BELLEY-COTE E, et al. Surviving sepsis campaign guidelines 2021:highlights for the practicing clinician[J]. Pol Arch Intern Med, 2022, 132(7):16290-16291. doi:10.20452/pamw.16290.
[7]	SEVRANSKY J E, ROTHMAN R E, HAGER D N, et al. Effect of Vitamin C, thiamine, and hydrocortisone on ventilator- and vasopressor-free days in patients with sepsis:the VICTAS randomized clinical trial[J]. JAMA, 2021, 325(8):742-750. doi:10.1001/jama.2020.24505.
[8]	MOSKOWITZ A, HUANG D T, HOU P C, et al. Effect of ascorbic acid,corticosteroids,and thiamine on organ injury in septic shock:the ACTS randomized clinical trial[J]. JAMA, 2020, 324(7):642-650. doi:10.1001/jama.2020.11946.
[9]	中华医学会重症医学分会. 中国严重脓毒症/脓毒性休克治疗指南(2014)[J]. 中华内科杂志, 2015, 54(6):557-581.
	Branch of Critical Care Medicine of Chinese Medical Association. Chinese guidelines for the treatment of severe sepsis/septic shock(2014)[J]. Chin J Intern Med, 2015, 54(6):557-581. doi:10.3760/cma.j.issn.0578-1426.2015.06.021.
[10]	MORENO R, RHODES A, PIQUILLOUD L, et al. The sequential organ failure assessment (SOFA) score:has the time come for an update?[J]. Crit Care, 2023, 27(1):15-16. doi:10.1186/s13054-022-04290-9.
[11]	HANSEN C K, ISSA M, BALAJI L, et al. Performance of the APACHE Ⅱand SOFA scores in diabetic ketoacidosis[J]. J Intensive Care Med, 2022, 37(6):715-720. doi:10.1177/08850666211023718.
[12]	ESPOSITO S, DE SIMONE G, BOCCIA G, et al. Sepsis and septic shock:new definitions,new diagnostic and therapeutic approaches[J]. J Glob Antimicrob Resist, 2017, 10:204-212. doi: 10.1016/j.jgar.2017.06.013.
[13]	JACOBI J. The pathophysiology of sepsis-2021 update:part 2,organ dysfunction and assessment[J]. Am J Health Syst Pharm,2022, 79(6):424-436. doi:10.1093/ajhp/zxab393.
[14]	IGLESIAS J, VASSALLO A V, PATEL V V, et al. Outcomes of metabolic resuscitation using ascorbic acid,thiamine,and glucocorticoids in the early treatment of sepsis:the ORANGES trial[J]. Chest, 2020, 158(1):164-173. doi:10.1016/j.chest.2020.02.049.
[15]	王琳, 冯建宏. 硫胺素抗坏血酸和糖皮质激素在脓毒症治疗中的研究进展[J]. 中国急救医学, 2021, 41(9):821-825.
	WANG L, FENG J H. Research progress of thiamine,ascorbic acid and glucocorticoid in the treatment of sepsis[J]. Chinese Journal of Critical Care Medicine, 2021, 41(9):821-825. doi:10.3969/j.issn.1002-1949.2021.09.017.
[16]	AMMAR M A, AMMAR A A, CONDENI M S, et al. Vitamin C for sepsis and septic shock[J]. Am J Ther, 2021, 28(6):649-679. doi:10.1097/MJT.0000000000001423.
[17]	FOWLER C, RAOOF N, PASTORES S M. Sepsis and adrenal insufficiency[J]. J Intensive Care Med, 2023, 38(11):987-996. doi:10.1177/08850666231183396.
[18]	LYU Q Q, ZHENG R Q, CHEN Q H, et al. Early administration of hydrocortisone,vitamin C, and thiamine in adult patients with septic shock:a randomized controlled clinical trial[J]. Crit Care, 2022, 26(1):295-296. doi:10.1186/s13054-022-04175-x.
[19]	杨蕊, 蒋佳维, 王勇强. 联合使用维生素C,维生素B1及氢化可的松对脓毒症血小板减少症患者疗效的影响[J]. 中国中西医结合急救杂志, 2021, 28(1):48-51.
	YANG R, JIANG J W, WANG Y Q. Clinical efficacy of combination of vitamin C,thiamine and hydrocortisone in treatment of septic patients with thrombocytopenia[J]. Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care, 2021, 28(1):48-51. doi:10.3969/j.issn.1008-9691.2021.01.012.
[20]	WILLIAMS ROBERSON S, NWOSU S, COLLAR E M, et al. Association of vitamin C,thiamine,and hydrocortisone infusion with long-term cognitive,psychological,and functional outcomes in sepsis survivors:a secondary analysis of the vitamin C,thiamine,and steroids in sepsis randomized clinical trial[J]. JAMA Netw Open, 2023, 6(2):2303-2305. doi:10.1001/jamanetworkopen.2023.0380.
[21]	WANG K, YIN L, SONG Y, et al. The use of hydrocortisone,ascorbic acid and thiamine in patients with sepsis and septic shock-a systematic review[J]. J Pharm Pract, 2023, 36(4):933-940. doi:10.1177/08971900221097193.
[22]	NA W, SHEN H, LI Y, et al. Hydrocortisone,ascorbic acid,and thiamine (HAT) for sepsis and septic shock:a meta-analysis with sequential trial analysis[J]. J Intensive Care, 2021, 9(1):75-76. doi:10.1186/s40560-021-00589-x.
[23]	LAMONTAGNE F, MASSE M H, MENARD J, et al. Intravenous vitamin C in adults with sepsis in the intensive care unit[J]. N Engl J Med, 2022, 386(25):2387-2398. doi:10.1056/NEJMoa2200644.
[24]	GROSSESTREUER A V, MOSKOWITZ A, ANDERSEN L W, et al. Effect of ascorbic acid,corticosteroids,and thiamine on health-related quality of life in sepsis[J]. Crit Care Explor, 2020, 2(12):270-271. doi:10.1097/CCE.0000000000000270.
[25]	FUJII T, LUETHI N, YOUNG P J, et al. Effect of vitamin C,hydrocortisone, and thiamine vs hydrocortisone alone on time alive and free of vasopressor support among patients with septic shock:the VITAMINS randomized clinical trial[J]. JAMA, 2020, 323(5):423-431. doi:10.1001/jama.2019.22176.

组别	年龄/岁	男性	原发病
组别	年龄/岁	男性	重症肺炎	重症胰腺炎	腹腔感染	重症胆囊炎
常规治疗组	57.0±5.9	21（45.7）	12（26.1）	15（32.6）	11（23.9）	8（17.4）
HAT组	59.4±6.3	28（60.9）	17（37.0）	10（21.7）	13（28.3）	6（13.0）
t或χ²	1.904	2.140	2.314

组别	年龄/岁	男性	原发病
组别	年龄/岁	男性	重症肺炎	重症胰腺炎	腹腔感染	重症胆囊炎
常规治疗组	57.0±5.9	21（45.7）	12（26.1）	15（32.6）	11（23.9）	8（17.4）
HAT组	59.4±6.3	28（60.9）	17（37.0）	10（21.7）	13（28.3）	6（13.0）
t或χ²	1.904	2.140	2.314

组别	循环稳定时间/h	血管活性药物应用时间/d	激素使用时间/d	机械通气时间/d	CRRT时间/d	ICU治疗时间/d	总住院时间/d
常规治疗组	13.27±2.62	5.95±1.03	3.25±0.41	7.91±1.27	12.61±1.89	14.57±2.06	18.92±4.12
HAT组	9.08±1.75	2.26±0.34	1.96±0.20	5.68±0.35	10.03±1.27	11.74±1.53	15.79±3.65
t	9.020^＊＊	13.073^＊＊	23.072^＊＊	11.481^＊＊	7.685^＊＊	7.480^＊＊	3.857^＊＊

组别	循环稳定时间/h	血管活性药物应用时间/d	激素使用时间/d	机械通气时间/d	CRRT时间/d	ICU治疗时间/d	总住院时间/d
常规治疗组	13.27±2.62	5.95±1.03	3.25±0.41	7.91±1.27	12.61±1.89	14.57±2.06	18.92±4.12
HAT组	9.08±1.75	2.26±0.34	1.96±0.20	5.68±0.35	10.03±1.27	11.74±1.53	15.79±3.65
t	9.020^＊＊	13.073^＊＊	23.072^＊＊	11.481^＊＊	7.685^＊＊	7.480^＊＊	3.857^＊＊

组别	APACHEⅡ评分		t₂	SOFA评分		t₂
组别	治疗前	治疗后	t₂	治疗前	治疗后	t₂
常规治疗组	25.0±2.7	16.7±1.8	19.011^＊＊	14.1±2.2	7.5±1.3	16.066^＊＊
HAT组	24.1±2.1	11.1±1.3	31.607^＊＊	13.6±1.7	5.4±0.7	31.517^＊＊
t₁	1.754	16.985^＊＊		1.079	10.142^＊＊